Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 80-87, 2016.
Article
Dans En
| WPRIM
| ID: wpr-170078
Responsable en Bibliothèque :
WPRO
ABSTRACT
PURPOSE:
This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. MATERIALS ANDMETHODS:
Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m(2) of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. The primary end point was progression-free survival (PFS) at 6 months.RESULTS:
A total of 95 patients were enrolled (47 for pemetrexed and 48 for gefitinib). Most patients were male (72%) and current/ex-smokers (69%), and 80% had non-squamous cell carcinoma. The epidermal growth factor receptor (EGFR) mutation status was determined in 38 patients (40%); one patient per each arm was positive for EGFR mutation. The 6-month PFS rates were 22% and 15% for pemetrexed and gefitinib, respectively (p=0.35). Both arms showed an identical median PFS of 2.0 months and a median overall survival (OS) of 8.5 months. In EGFR wild-type patients, higher response rate (RR) and longer PFS as well as OS were achieved via pemetrexed compared with gefitinib, although there were no significant differences (RR 39% vs. 9%, p=0.07; median PFS 6.6 months vs. 3.1 months, p=0.45; median OS 29.6 months vs. 12.9 months, p=0.62). Toxicities were mild in both treatment arms. Frequently reported toxicities were anemia and fatigue for pemetrexed, and skin rash and anorexia for gefitinib.CONCLUSION:
Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. However, pemetrexed is considered more effective than gefitinib for EGFR wild-type patients.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Bras
/
Anorexie
/
Carcinome pulmonaire non à petites cellules
/
Survie sans rechute
/
Traitement médicamenteux
/
Exanthème
/
Fatigue
/
Récepteurs ErbB
/
Anémie
Type d'étude:
Clinical_trials
Limites du sujet:
Humans
/
Male
langue:
En
Texte intégral:
Cancer Research and Treatment
Année:
2016
Type:
Article